Takis, Rottapharm in vaccine deal

(ANSA) - Rome, June 3 - Italian biotech companies Takis and Rottapharm Biotech on Wednesday reached a deal to develop a vaccine against the coronavirus conceived by Takis and called COVID-eVax.
    Within the framework of the accord, a statement said, Rottapharm Biotech will place at Takis's disposal its experience in the development of innovative drugs and financial support up to at least the completion of phases one and two of clinical trials.
    The first three million euros have already been agreed for ongoing programmes and human testing is expected this autumn.